Immunome, Inc. (IMNM) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Is Immunome, Inc. stock overvalued or undervalued in 2026?
As of November 2, 2026, Immunome, Inc. (IMNM) trades at $19.59 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Immunome, Inc.
Market cap $2B · 52 weeks $15 – $30 (34 % below the high) · P/E no earnings · Dividend none · Next earnings November 5, 2026 · expected EPS -$0.60 · Closing price, Nov 2 · accounts published Aug 11.
- Valuation: P/Sales 89.1× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 4 of 4 pass
- Cash Runway 41 months, passes.
- Total Debt 0.0×, passes.
- R&D / Market cap 10.2 %, passes, near the threshold.
- Market cap / Cash 2.6×, passes.
- Annual cash burn $2.19, info.
Against its peers (reference peers) — Immunome, Inc.: P/E —; EV/EBITDA —; ROIC -51.1 %; $2.3B. Harmony Biosciences Holdings, Inc. (P/E 12.3×; EV/EBITDA 6.7×; ROIC 15.0 %; $2.2B), ADMA Biologics, Inc. (P/E 15.8×; EV/EBITDA 10.9×; ROIC 27.6 %; $2.5B), Aurinia Pharmaceuticals Inc. (P/E 7.0×; EV/EBITDA 11.4×; ROIC 20.9 %; $2.1B).
Profitability
| Return on Equity | -50.56% |
| Return on Invested Capital | -51.06% |
| Return on Assets | -44.98% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 15.08 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 21.61 |
Price Performance
| 1 month | -6.27% |
| 3 months | -23.24% |
| Year-to-date | -8.80% |
| 1 year | +15.24% |
| 3 years | +123.89% |
| 5 years | -13.47% |
Related companies: CLDX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of IMNM: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks